Delving into the Latest Updates on CytoCares Shanghai, Inc. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Trispecific T-cell engager (TriTE)

Trispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Trispecific antibody	1
Trispecific T-cell engager (TriTE)	1

Top 5 Target	Count

CD19 x CD28 x CD3	1
CD molecules	1

（1）评估CC312在复发/难治性CD19阳性的B细胞性非霍奇金淋巴瘤和B淋巴细胞白血病患者中的安全性和耐受性；（2）探索CC312的剂量限制性毒性（DLT），并确定CC312在复发/难治CD19阳性的B细胞性非霍奇金淋巴瘤患者中的最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。

[Translation]

(1) Evaluate the safety and tolerability of CC312 in patients with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma and B-cell leukemia; (2) Explore the dose-limiting toxicity (DLT) of CC312 and determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of CC312 in patients with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma.

Start Date25 Jul 2023

Sponsor / Collaborator

CytoCares Shanghai, Inc.Startup

100 Clinical Results associated with CytoCares Shanghai, Inc.

Login to view more data

0 Patents (Medical) associated with CytoCares Shanghai, Inc.

Login to view more data

1

Literatures (Medical) associated with CytoCares Shanghai, Inc.

01 Feb 2024·Immunotherapy

A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement

Article

Author: Chen, Li ; Zhu, Huaxing ; Ren, Pu ; Tong, Li ; Xu, Qiming ; Xian, Weiwei ; Yang, Yingying ; Li, Debin ; Qian, Wenjing ; Yu, Weiwei ; Pan, Fangfang ; Zhu, Xufeng ; Dai, Ruixue ; Ding, Jianfeng

Aim: A novel CD19xCD3xCD28 trispecific antibody with a tandem single-chain variable fragments (scFv) structure was developed for the treatment of B-cell malignancies. Methods: The trispecific antibody in inducing tumor-directed T-cell activation and cytotoxicity was evaluated in vitro and in vivo and compared with its bispecific counterpart BiTE-CD19xCD3 lacking a CD28-targeting domain. Results: The trispecific antibody with a co-stimulatory domain exhibited augmented T-cell activation and memory T-cell differentiation capability and it induced faster tumor cell lysis than the bispecific antibody. RNAseq analysis revealed that the trispecific antibody modulates CD3/TCR complex-derived signal and upregulates antiapoptotic factors to influence the survival of T cells. Conclusion: By CD3/CD28 co-engagement, the trispecific antibody demonstrated its advantages in T-cell immunity and potential use as a more powerful and long-lasting T-cell engager.

100 Deals associated with CytoCares Shanghai, Inc.

Login to view more data

100 Translational Medicine associated with CytoCares Shanghai, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1 Clinical

Login to view more data